[go: up one dir, main page]

WO2001053535A3 - Method of detecting neoplastic, hyperplastic, cytologically dysplastic and/or premalignant cellular growth or proliferation - Google Patents

Method of detecting neoplastic, hyperplastic, cytologically dysplastic and/or premalignant cellular growth or proliferation Download PDF

Info

Publication number
WO2001053535A3
WO2001053535A3 PCT/US2001/001956 US0101956W WO0153535A3 WO 2001053535 A3 WO2001053535 A3 WO 2001053535A3 US 0101956 W US0101956 W US 0101956W WO 0153535 A3 WO0153535 A3 WO 0153535A3
Authority
WO
WIPO (PCT)
Prior art keywords
hyperplastic
proliferation
cellular growth
neoplastic
survivin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/001956
Other languages
French (fr)
Other versions
WO2001053535A2 (en
Inventor
W Stephen Nichols
Raymond C K Chan
Lisa Jouben-Steele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Priority to AU2001231025A priority Critical patent/AU2001231025A1/en
Publication of WO2001053535A2 publication Critical patent/WO2001053535A2/en
Anticipated expiration legal-status Critical
Publication of WO2001053535A3 publication Critical patent/WO2001053535A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Disclosed is a method of neoplastic, hyperplastic, cytologically dysplastic and/or premalignant cellular growth or proliferation in a human subject that involves collecting a sample from the human subject of a bodily substance, such as urine, blood, semen, saliva, mucus, feces, or cellular material, which contains the human subject's nucleic acid or protein. Expression and/or overexpression of nucleic acid or protein products of survivin gene, detected in the bodily substance, is diagnostic for the presence of neoplastic, hyperplastic, cytologically dysplastic and/or premalignant cellular growth or proliferation. Detection is through amplification by molecular biological techniques of survivin-specific nucleic acids and analysis of the amplification products, or by immunochemical assay for Survivin protein. Embodiments of the method are disclosed for detecting a neoplastic, hyperplastic, cytologically dysplastic and/or premalignant cellular growth or proliferation of the human urinary tract, such as a urinary tract neoplasm. Also disclosed are survivin gene-specific primers and probes, primer sets, and diagnostic kits containing them.
PCT/US2001/001956 2000-01-20 2001-01-19 Method of detecting neoplastic, hyperplastic, cytologically dysplastic and/or premalignant cellular growth or proliferation Ceased WO2001053535A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001231025A AU2001231025A1 (en) 2000-01-20 2001-01-19 Method of detecting neoplastic, hyperplastic, cytologically dysplastic and/or premalignant cellular growth or proliferation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48819100A 2000-01-20 2000-01-20
US09/488,191 2000-01-20

Publications (2)

Publication Number Publication Date
WO2001053535A2 WO2001053535A2 (en) 2001-07-26
WO2001053535A3 true WO2001053535A3 (en) 2002-08-08

Family

ID=23938695

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/001956 Ceased WO2001053535A2 (en) 2000-01-20 2001-01-19 Method of detecting neoplastic, hyperplastic, cytologically dysplastic and/or premalignant cellular growth or proliferation

Country Status (2)

Country Link
AU (1) AU2001231025A1 (en)
WO (1) WO2001053535A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4368110B2 (en) * 2001-01-12 2009-11-18 エール ユニヴァーシティ Detection of survivin in biological fluids of cancer patients
US7776518B2 (en) 2001-01-12 2010-08-17 Yale University Detection of survivin in the biological fluids of cancer patients
JP2005503807A (en) * 2001-09-24 2005-02-10 ハイブリドン・インコーポレイテッド Antisense oligonucleotides and methods for inducing tumor cell death
EP2011885B1 (en) * 2005-02-10 2015-04-22 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
CN103409413B (en) * 2013-07-12 2015-02-04 福建农林大学 Sugarcane genome endogenous reference gene fructose-6-phosphate 2-kinase gene PCR (polymerase chain reaction) primer sequences and amplification method
CN108374047B (en) * 2018-02-09 2021-08-24 王煜 Kit for detecting bladder cancer based on high-throughput sequencing technology

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018781A1 (en) * 1998-09-29 2000-04-06 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018781A1 (en) * 1998-09-29 2000-04-06 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JOUBEN-STEELE L M ET AL.: "Survivin expression in the surveillance of urothelial neoplasia", LABORATORY INVESTIGATION, vol. 79, no. 1, January 1999 (1999-01-01), pages 99A, XP008003632 *
MONZO M ET AL.: "A novel anti-apoptosis gene: Re-expression of Survivin messenger RNA as a prognosis marker in non-small lung cancers", JOURNAL OF CLINICAL ONCOLOGY, vol. 17, July 1999 (1999-07-01), pages 2100 - 2104, XP008003534 *
SAITOH Y ET AL.: "Analysis of Bcl-2, Bax and Survivin genes in uterine cancer", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 15, July 1999 (1999-07-01), pages 137 - 141, XP008003633 *
SHASTRI S ET AL.: "Survivin RNA expression in urine sediments compared to bladder biopsy results", MODERN PATHOLOGY, vol. 14, January 2002 (2002-01-01), pages 123A, XP008003630 *
SMITH S D ET AL.: "Urine detection of survivin and diagnosis of bladder cancer", JAMA, vol. 285, 17 January 2001 (2001-01-17), pages 324 - 328, XP008003639 *
WEN S F ET AL.: "Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models", CANCER GENE THERAPY, vol. 7, November 2000 (2000-11-01), pages 1469 - 1480, XP008003638 *

Also Published As

Publication number Publication date
WO2001053535A2 (en) 2001-07-26
AU2001231025A1 (en) 2001-07-31

Similar Documents

Publication Publication Date Title
Kumar et al. Recent optical sensing technologies for the detection of various biomolecules
CN101443456B (en) Purification process and test kit
US20040110167A1 (en) Lateral flow system for nucleic acid detection
KR930701597A (en) Use of recombinant BPI protein, BPI protein and method for preparing same
NZ601022A (en) Diagnosis and treatment of cancer using anti-ereg antibody
CN105190310A (en) A biosensor device to target analytes in situ, in vivo, and/or in real time, and methods of making and using the same
RU2006101395A (en) METHOD FOR DETECTING NEOPLASTIC DISEASES BASED ON A SOLUBILIZED PHYSIOLOGICAL SAMPLE
EP1026262A3 (en) Oligonucleotide primers for efficient detection of hepatitis C virus (HCV) and methods of use thereof
WO1999014377A3 (en) Detection and identification of human papillomavirus by pcr and type-specific reverse hybridization
CN114839374A (en) Method for accurate diagnosis of disease-targeted biomarkers in liquid biopsies
WO2003033735A3 (en) Test strip assay system and method for the detection of specific nucleic acid sequences
WO2006063065A3 (en) Detection of nucleic acids from multiple types of human papillomaviruses
RU2014122607A (en) METHODS FOR DETERMINING A PATIENT'S SUSCEPTIBILITY TO IN-HOSPITAL INFECTION AND FORMING A FORECAST OF SEPTIC SYNDROME DEVELOPMENT
CN114150089A (en) CRISPR-Cas-based trans-cleavage and gFET nucleic acid detection
WO2001053535A3 (en) Method of detecting neoplastic, hyperplastic, cytologically dysplastic and/or premalignant cellular growth or proliferation
EP1609874A3 (en) System for searching for and identifying pathogenic agents
WO2003089934A3 (en) Method for diagnosing inflammatory diseases and infections by the determination of lasp-1/lap-1
FI961678A0 (en) Primers and probes for amplification and detection of CMV nucleic acid
CN101525671B (en) Highly pathogenic porcine reproductive and respiratory syndrome virus detection reagent kit and application thereof
CN110499311A (en) A method for extracting Schistosoma DNA from feces and its rapid identification method for LF-RPA
SE9900615L (en) Method and kit for early prediction of cancer
WO2006089219A3 (en) Neoepitope detection of disease using protein arrays
WO2001053817A3 (en) Methods of and apparatus for separating and detecting nucleic acid
WO2002018645A3 (en) 5t4 rna in plasma and serum as a marker for neoplastic disease
WO2007029809A1 (en) Method for test on latent viral infection and kit for use in the test

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP